Eli Lilly has a promising outlook with significant growth prospects in the weight management drug market, driven by products like tirzepatide and orforglipron. The company is also developing retatrutide, a potential game-changer in the pharmaceutical industry. On the other hand, Berkshire Hathaway faces challenges, including Warren Buffett stepping down as CEO and Apple, its largest holding, dealing with tariffs and competition in the AI market. Investors may need to be patient for Berkshire Hathaway to deliver outstanding returns compared to Eli Lilly through 2030.

Despite Berkshire Hathaway’s strengths, Eli Lilly’s growth potential and innovative products may lead to outperformance in the coming years, making it a compelling investment opportunity. Investors should consider both companies’ strengths and weaknesses before making investment decisions.

Read more at Nasdaq, Inc.: Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030